FoxO4 Inhibits NF-κB and Protects Mice Against Colonic Injury and Inflammation

Departmentsof Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9148, USA.
Gastroenterology (Impact Factor: 16.72). 07/2009; 137(4):1403-14. DOI: 10.1053/j.gastro.2009.06.049
Source: PubMed


FoxO4 is a member of the forkhead box transcription factor O (FoxO) subfamily. FoxO proteins are involved in diverse biological processes. In this study, we examine the role of FoxO4 in intestinal mucosal immunity and inflammatory bowel disease (IBD).
Foxo4-null mice were subjected to trinitrobenzene sulfonic acid (TNBS) treatment. Microarray analysis and quantitative reverse transcription polymerase chain reaction were used to identify the cytokine transcripts that were altered by Foxo4 deletion. The effects of Foxo4 deficiency on the intestinal epithelial permeability and levels of tight junction proteins were examined by permeable fluorescent dye and Western blot. The molecular and cellular mechanisms by which FoxO4 regulates the mucosal immunity were explored through immunologic and biochemical analyses. The expression level of FoxO4 in intestinal epithelial cells of patients with IBD was examined with immunohistochemistry.
Foxo4-null mice were more susceptible to TNBS injury-induced colitis. The chemokine CCL5 is significantly up-regulated in the colonic epithelial cells of Foxo4-null mice, with increased recruitment of CD4(+) intraepithelial T cells and up-regulation of cytokines interferon-gamma and tumor necrosis factor-alpha in the colon. Foxo4 deficiency also resulted in an increase in intestinal epithelial permeability and down-regulation of the tight junction proteins ZO-1 and claudin-1. Mechanistically, FoxO4 inhibited the transcriptional activity of nuclear factor-kappaB (NF-kappaB), and Foxo4 deficiency is associated with increased NF-kappaB activity in vivo. FoxO4 transcription is transiently repressed in response to TNBS treatment and in patients with IBD.
These results indicate that FoxO4 is an endogenous inhibitor of NF-kappaB and identify a novel function of FoxO4 in the regulation of NF-kappaB-mediated mucosal immunity.

Download full-text


Available from: Yan Peng, Jan 13, 2015
  • Source
    • "Global deletion of FOXO3 is not lethal but affects lymph proliferation, widespread organ inflammation [4], age-dependent infertility [3], and decline in the neural stem cell pool [5]. Global deletion of FOXO4 exacerbates colitis in response to inflammatory stimuli [6]. Global deletion of FOXO6 displays normal learning but impaired memory consolidation [7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Members of the class O of forkhead box transcription factors (FOXO) have important roles in metabolism, cellular proliferation, stress resistance, and apoptosis. The activity of FOXOs is tightly regulated by posttranslational modification, including phosphorylation, acetylation, and ubiquitylation. Activation of cell survival pathways such as phosphoinositide-3-kinase/AKT/IKK or RAS/mitogen-activated protein kinase phosphorylates FOXOs at different sites which regulate FOXOs nuclear localization or degradation. FOXO transcription factors are upregulated in a number of cell types including hepatocytes, fibroblasts, osteoblasts, keratinocytes, endothelial cells, pericytes, and cardiac myocytes. They are involved in a number of pathologic and physiologic processes that include proliferation, apoptosis, autophagy, metabolism, inflammation, cytokine expression, immunity, differentiation, and resistance to oxidative stress. These processes impact a number of clinical conditions such as carcinogenesis, diabetes, diabetic complications, cardiovascular disease, host response, and wound healing. In this paper, we focus on the potential role of FOXOs in different disease models and the regulation of FOXOs by various stimuli.
    BioMed Research International 04/2014; 2014(3):925350. DOI:10.1155/2014/925350 · 2.71 Impact Factor
  • Source
    • "FOXO transcription factors are activated under proinflammatory and oxidative environments via post-translational modifications by a variety of kinases including JNK [36] [37] causing nuclear translocation. Although FOXO1 and 3a have been shown to promote pro-inflammatory environments [38] [39], FOXO4 activation has been shown to be protective against inflammation and oxidative stress [40] [41]. In unrelated studies, we observed FOXO4 to be the highest expressed FOXO isoform in the placenta (unpublished data); therefore FOXO4 may serve as an adaptive mechanism for the placenta to respond to cellular stress. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Maternal obesity is associated with placental lipotoxicity, oxidative stress, and inflammation, where MAPK activity may play a central role. Accordingly, we have previously shown that placenta from obese women have increased activation of MAPK-JNK. Here, we performed RNA-sequencing on term placenta from twenty-two subjects who were dichotomized based on pre-pregnancy BMI into lean (BMI 19- 24 kg/m2; n = 12) and obese groups (BMI, 32-43 kg/m2; n = 12). RNA-seq revealed 288 genes to be significantly different in placenta from obese women by >1.4-fold. GO analysis identified genes related to lipid metabolism, angiogenesis, hormone activity, and cytokine activity to be altered in placenta from obese women. Indicative of a lipotoxic environment, increased placental lipid and CIDEA protein were associated with decreased AMPK and increased activation of NF-κB(p65) in placenta from obese women. Furthermore, we observed a 25% decrease in total antioxidant capacity and increased nuclear FOXO4 localization in placenta from obese women that was significantly associated with JNK activation, suggesting that maternal obesity may also be associated with increased oxidative stress in placenta. Maternal obesity was also associated with decreased HIF-1α protein expression, suggesting a potential link between increased inflammation/oxidative stress and decreased angiogenic factors. Together, these findings indicate that maternal obesity leads to a lipotoxic placental environment that is associated with decreased regulators of angiogenesis and increased markers of inflammation and oxidative stress.
    Placenta 03/2014; 35(3). DOI:10.1016/j.placenta.2014.01.003 · 2.71 Impact Factor
  • Source
    • ". FOXO1 deficiency induces inflammatory bowel disease [108], which is also shown in FOXO4-deficient mice [109]. However, in neutrophilic inflammation, such as rheumatoid arthritis and peritonitis, FOXO3 levels are elevated and required to suppress proapoptotic responses in neutrophils [110] [111]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sirtuin1 (SIRT1) regulates inflammation, aging (lifespan and healthspan), calorie restriction/energetics, mitochondrial biogenesis, stress resistance, cellular senescence, endothelial functions, apoptosis/autophagy, and circadian rhythms through deacetylation of transcription factors and histones. SIRT1 level and activity are decreased in chronic inflammatory conditions and aging where oxidative stress occurs. SIRT1 is regulated by a NAD(+)-dependent DNA repair enzyme poly(ADP-ribose)-polymerase-1 (PARP-1), and subsequent NAD(+) depletion by oxidative stresses may have consequent effects on inflammatory and stress responses as well as cellular senescence. SIRT1 has been shown to undergo covalent oxidative modifications by cigarette smoke-derived oxidants/aldehydes, leading to post-translational modifications, inactivation, and protein degradation. Furthermore, oxidant/carbonyl stress-mediated reduction of SIRT1 leads to the loss of its control on acetylation of target proteins including p53, RelA/p65 and FOXO3, thereby enhancing the inflammatory, pro-senescent and apoptotic responses, as well as endothelial dysfunction. In this review, the mechanisms of cigarette smoke/oxidant-mediated redox post-translational modifications of SIRT1 and its role in PARP1, NF-κB activation, FOXO3 and eNOS regulation, as well as chromatin remodeling/histone modifications during inflammaging are discussed. Furthermore, we also discussed various novel ways to activate SIRT1 either directly or indirectly, which may have therapeutic potential in attenuating inflammation and premature senescence involved in chronic lung diseases.
    Free Radical Biology and Medicine 03/2013; 61. DOI:10.1016/j.freeradbiomed.2013.03.015 · 5.74 Impact Factor
Show more